- Home
- GMAB vs BMRN Comparison
GMAB vs BMRN Comparison
Compare GMAB & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- BMRN
- Stock Information
- Founded
- GMAB 1999
- BMRN 1996
- Country
- GMAB Denmark
- BMRN United States
- Employees
- GMAB 2638
- BMRN N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- GMAB Health Care
- BMRN Health Care
- Exchange
- GMAB Nasdaq
- BMRN Nasdaq
- Market Cap
- GMAB 13.4B
- BMRN 12.1B
- IPO Year
- GMAB N/A
- BMRN 1999
- Fundamental
- Price
- GMAB $22.25
- BMRN $57.08
- Analyst Decision
- GMAB Buy
- BMRN Buy
- Analyst Count
- GMAB 9
- BMRN 22
- Target Price
- GMAB $39.17
- BMRN $93.43
- AVG Volume (30 Days)
- GMAB 1.3M
- BMRN 2.4M
- Earning Date
- GMAB 05-08-2025
- BMRN 05-01-2025
- Dividend Yield
- GMAB N/A
- BMRN N/A
- EPS Growth
- GMAB 276.80
- BMRN 152.82
- EPS
- GMAB 18.36
- BMRN 2.71
- Revenue
- GMAB $3,230,902,140.00
- BMRN $2,950,227,000.00
- Revenue This Year
- GMAB $747.74
- BMRN $12.27
- Revenue Next Year
- GMAB $14.81
- BMRN $10.08
- P/E Ratio
- GMAB $1.21
- BMRN $20.94
- Revenue Growth
- GMAB 25.43
- BMRN 19.36
- 52 Week Low
- GMAB $17.24
- BMRN $52.93
- 52 Week High
- GMAB $28.56
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- GMAB 64.68
- BMRN 43.25
- Support Level
- GMAB $20.88
- BMRN $55.15
- Resistance Level
- GMAB $22.15
- BMRN $57.81
- Average True Range (ATR)
- GMAB 0.39
- BMRN 1.27
- MACD
- GMAB 0.14
- BMRN -0.00
- Stochastic Oscillator
- GMAB 94.62
- BMRN 39.65
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.